KCT0002531
Completed
未知
Efficacy of repeated intravitreal Lucentis (Ranibizumab) injection according to the genotypic characteristics of exudative age-related macular degeneration in Koreans
ConditionsDiseases of the eye and adnexa
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the eye and adnexa
- Sponsor
- Seoul National University Hospital
- Enrollment
- 300
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. An age over 50 years
- •2\. Exudative age\-related macular degeneration patients with subfoveal leakage on fluorescein angiogram (FA) and exudative change on OCT who are treated with intravitreal anti\-VEGF injections
- •3\. Agreement to genetic analysis
Exclusion Criteria
- •1\. any previous treatment for exudative age\-related macular degeneration such as laser photocoagulation, PDT, or anti\-VEGF injection; 2\. other concomitant ocular disease such as diabetic retinopathy, retinal vascular disease, epiretinal membrane, and high myopia; 3\. previous vitreoretinal surgery; and (4\) presence of a disciform macular scar or atrophy.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)Macular EdemaRetinal Vein OcclusionNCT00942864Novartis Korea Ltd.40
Active, not recruiting
Not Applicable
The effect of Lucentis (ranibizumab) on retinal function in diabetic patients with visual impairment and diabetic svelling of the makulaDiabetic makula edema with visual impairmentMedDRA version: 14.0Level: HLGTClassification code 10012653Term: Diabetic complicationsSystem Organ Class: 10014698 - Endocrine disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2011-004613-17-SEInst of Ophtalmology Lund University hospital
Unknown
Phase 2
Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein OcclusionRetinal Vein OcclusionMacular EdemaNCT01123564University of Pecs40
Completed
Not Applicable
Intraocular injection conbercept is effective to improve vision, relieve symptoms for patients suffered from polypoidal choroidal vasculopathyISRCTN10396126Sun Yat-sen University45
Terminated
Phase 2
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)Choroidal NeovascularizationWet Macular DegenerationNCT03452527Iconic Therapeutics, Inc.15